Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Bruker

BRKR Healthcare Unknown Updated July 31, 2026
$62.80
52W $28.53 – $65.30
50/100
$9.57B
-262.9
1.29
AI Committee Verdict
Watch
Conviction: Moderate · 67% agreement · 6 analysts
+2.7%
-0.1%
18.27:1
Moderate

Is BRKR Bullish or Bearish?

Mixed. Innellis AI committee rates Bruker (BRKR) Watch with a composite score of 50/100 , based on 6 analysts with 67% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +9.70 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -10.30 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Technical Analyst sees a compelling case — price structure making higher highs and higher lows. Growth Analyst remains cautious — growth rate is decelerating quarter over quarter -- the trend line matters more than the level. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • ROE of only -0.5% -- cheap may mean cheap for a reason — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • Price trading above the upper Bollinger Band -- stretched — Technical
  • News sentiment is negative (-0.20 across 5 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
50/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 84%
of 93 Healthcare peers
Value Analyst neutral
42 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -0.5% -- cheap may mean cheap for a reason
Growth Analyst bearish
38 / 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bullish
68 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− Price trading above the upper Bollinger Band -- stretched
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
51 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.20 across 5 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 51.5 to 50.3.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Technical Analyst: +1 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
57.7
Neutral
MACD Histogram
0.155
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Mixed
Support
$62.71
Resistance
$64.53
Bollinger %B
0.83
Inside Bands
Price vs Moving Averages
EMA 9
$61.72 Above
EMA 21
$60.31 Above
EMA 50
$56.55 Above
EMA 200
$47.83 Above

Fundamental Analysis

Valuation
66
Growth
43
Profitability
0
Financial Health
77
Cash Flow
36
Valuation
P/E Ratio -262.9×
P/B Ratio 3.91×
PEG Ratio 2.33
Dividend Yield 0.00%
52W High $65.30
52W Low $28.53
Quality & Growth
ROE -0.4%
ROA -0.1%
Gross Margin 45.6%
Operating Margin 5.9%
Revenue Growth YoY
Debt / Equity 0.68
AI Fundamental Assessment
P/E ratio of -262.9 (inexpensive relative to a 15-40x range); Price-to-book of 3.9x; PEG ratio of 2.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -0.0%; Return on assets of -0.0%; Net margin of -0.0%; Gross margin of 0.5%; Current ratio of 1.55 (healthy short-term liquidity); Debt-to-equity of 0.68; Free cash flow margin of 0.4% (thin cash generation); Free cash flow per share is positive (0.34); Most recent quarter beat estimates by 30.1%; EPS growth decelerating (+31.1% -> -47.5% QoQ); Analyst estimates falling over recent quarters
Get the Full BRKR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore BRKR Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime